Innovation for Neurodevelopmental Disorders
Developing AKAI315, a novel non-stimulant small molecule drug initially focused on ADHD, with a seasoned team that has started six biotech companies and brought five drugs to market.
About Anaka
Anaka Pharmaceuticals is focused on innovation for impaired executive functioning in people with ADHD and other neurological disorders.
Novel Drug Development
Pioneering AKAI315, a non-stimulant small molecule drug designed to address impaired executive functioning in people with ADHD and other neurological disorders.
Neurological Focus
Dedicated to improving outcomes for patients with ADHD and neurodevelopmental disorders through innovative therapeutic approaches.
Experienced Leadership
Our seasoned founding team has started six biotech companies and successfully brought five drugs to market.
Our Pipeline
AKAI315: A Novel Approach to ADHD Treatment
AKAI315 is a non-stimulant small molecule drug initially focused on ADHD. Unlike traditional stimulant-based treatments, our approach targets impaired executive functioning through a novel mechanism of action.
ADHD
Primary Indication
Non-Stimulant
Mechanism Class
Our Science
Targeting Executive Function Through a Novel Mechanism
Executive functioning encompasses the cognitive processes that regulate attention, behavior, and emotional responses. Impairment in these processes is a hallmark of ADHD and other neurological conditions.
Our research focuses on a novel molecular pathway that may improve executive functioning without the side effects commonly associated with stimulant medications.
Our Team
Built by Industry Veterans
Our seasoned founding team brings decades of experience in drug development, clinical trials, and biotech company building.
6
Biotech Companies Founded
5
Drugs Brought to Market
100+
Years Combined Experience
Boston
Greater Boston HQ
Get in Touch
Contact Us
Interested in learning more about Anaka Pharmaceuticals or AKAI315? We would love to hear from you.
Location
Greater Boston Area